[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PT2611779T - Formas cristalinas de um inibidor do fator xa - Google Patents

Formas cristalinas de um inibidor do fator xa

Info

Publication number
PT2611779T
PT2611779T PT117574673T PT11757467T PT2611779T PT 2611779 T PT2611779 T PT 2611779T PT 117574673 T PT117574673 T PT 117574673T PT 11757467 T PT11757467 T PT 11757467T PT 2611779 T PT2611779 T PT 2611779T
Authority
PT
Portugal
Prior art keywords
inhibitor
factor
crystalline forms
crystalline
forms
Prior art date
Application number
PT117574673T
Other languages
English (en)
Inventor
Pandey Anjali
R Capodanno Vincent
Corcoran Liam
Mcnevin Michael
Zoraida Arroyo Itzia
M Wenslow Robert
G Ball Richard
L Margelefsky Eric
K Maher Timothy
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of PT2611779T publication Critical patent/PT2611779T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT117574673T 2010-09-01 2011-08-31 Formas cristalinas de um inibidor do fator xa PT2611779T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37933910P 2010-09-01 2010-09-01
US201161454396P 2011-03-18 2011-03-18

Publications (1)

Publication Number Publication Date
PT2611779T true PT2611779T (pt) 2016-11-21

Family

ID=45773260

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117574673T PT2611779T (pt) 2010-09-01 2011-08-31 Formas cristalinas de um inibidor do fator xa

Country Status (13)

Country Link
US (1) US8946269B2 (pt)
EP (1) EP2611779B1 (pt)
JP (4) JP2013536864A (pt)
CN (1) CN103261161B (pt)
AR (1) AR082804A1 (pt)
AU (1) AU2011295909B2 (pt)
CA (1) CA2810004C (pt)
ES (1) ES2603084T3 (pt)
IL (1) IL224698A (pt)
NZ (1) NZ608442A (pt)
PT (1) PT2611779T (pt)
TW (1) TW201221128A (pt)
WO (1) WO2012031017A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
US20150224091A1 (en) * 2011-08-31 2015-08-13 Portola Pharmaceuticals, Inc. Prevention and treatment of thrombosis in medically ill patients
TWI616987B (zh) * 2012-03-16 2018-03-01 樂仕特拉公司 光子材料中介層的方法及系統
US20140346397A1 (en) 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
US9200268B2 (en) 2012-12-27 2015-12-01 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
CN104693114B (zh) * 2013-12-10 2019-08-16 四川海思科制药有限公司 一种贝曲西班的改进的制备方法
CN105085387A (zh) * 2014-05-20 2015-11-25 四川海思科制药有限公司 贝曲西班盐及其制备方法和用途
WO2017091757A1 (en) 2015-11-24 2017-06-01 Portola Pharmaceuticals, Inc. Isotopically enriched betrixaban
CN106995405A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种贝曲西班马来酸盐无定型物及其制备方法
WO2017208169A1 (en) * 2016-06-02 2017-12-07 Dr. Reddy’S Laboratories Limited Polymorphs of betrixaban & its maleate salt
EP3254674A1 (en) 2016-06-08 2017-12-13 Sandoz Ag Pharmaceutical compositions of betrixaban maleate
EP3293174A1 (en) 2016-09-09 2018-03-14 Sandoz Ag Crystalline salts of betrixaban
WO2018069936A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Polymorphs and solid dispersion of betrixaban and methods for the preparation thereof
CN107382897B (zh) * 2017-07-10 2021-05-04 浙江宏元药业股份有限公司 一种贝曲西班的中间体及其制备方法和应用
EP3510996A1 (en) * 2018-01-11 2019-07-17 Sandoz AG Pharmaceutical compositions of betrixaban
CN108570003A (zh) * 2018-06-01 2018-09-25 浙江宏元药业股份有限公司 一种贝曲西班马来酸盐的一水无定形及其制备方法
CN113905715A (zh) 2019-06-28 2022-01-07 宝洁公司 光增强处理方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226238D0 (en) 1992-12-16 1993-02-10 Scherer Ltd R P Encapsulation apparatus and process
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6844367B1 (en) 1999-09-17 2005-01-18 Millennium Pharmaceuticals, Inc. Benzamides and related inhibitors of factor Xa
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US6627646B2 (en) 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7696352B2 (en) 2004-06-18 2010-04-13 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
CA2565437A1 (en) 2004-06-18 2006-01-05 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
JP5227178B2 (ja) * 2005-11-08 2013-07-03 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
MX2008014193A (es) 2006-05-05 2009-03-31 Millennium Pharm Inc Inhibidores del factor xa.
US20080051578A1 (en) 2006-08-24 2008-02-28 Georg Dahmann Substituted biaryls, process for their manufacture and use thereof as medicaments
WO2008057972A1 (en) 2006-11-02 2008-05-15 Millennium Pharmaceuticals, Inc. Methods of synthesizing pharmaceutical salts of a factor xa inhibitor
NZ578180A (en) 2006-12-08 2012-02-24 Millennium Pharm Inc Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor
CA2674924A1 (en) 2007-01-05 2008-07-17 Millennium Pharmaceuticals, Inc. Factor xa inhibitors
CN103071154A (zh) 2007-04-13 2013-05-01 千年药品公司 用起因子xa抑制剂作用的化合物的组合抗凝治疗
BRPI0811000A2 (pt) 2007-05-02 2015-01-27 Portola Pharmaceutiacals Inc Terapia de combinação com um composto agindo como inibidor de receptor de adp de plaqueta
BR122022001846B1 (pt) 2007-09-28 2022-12-27 Portola Pharmaceuticals, Inc. Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento
AU2009314153B2 (en) 2008-11-14 2015-09-17 Alexion Pharmaceuticals, Inc. Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
US8394964B2 (en) * 2009-12-17 2013-03-12 Millennium Pharmaceuticals, Inc. Methods of synthesizing factor Xa inhibitors
AR082803A1 (es) 2010-09-01 2013-01-09 Portola Pharm Inc Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p

Also Published As

Publication number Publication date
ES2603084T3 (es) 2017-02-23
US20120071519A1 (en) 2012-03-22
AR082804A1 (es) 2013-01-09
EP2611779A1 (en) 2013-07-10
JP2019135258A (ja) 2019-08-15
CN103261161A (zh) 2013-08-21
JP2015232046A (ja) 2015-12-24
US8946269B2 (en) 2015-02-03
AU2011295909A1 (en) 2013-04-04
TW201221128A (en) 2012-06-01
CA2810004C (en) 2019-09-10
JP2013536864A (ja) 2013-09-26
JP2018024709A (ja) 2018-02-15
EP2611779B1 (en) 2016-08-10
CA2810004A1 (en) 2012-03-08
AU2011295909B2 (en) 2015-05-21
CN103261161B (zh) 2016-04-27
WO2012031017A1 (en) 2012-03-08
IL224698A (en) 2017-01-31
NZ608442A (en) 2015-04-24

Similar Documents

Publication Publication Date Title
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
ZA201301802B (en) Besylate salt of a btk inhibitor
SG10201500451TA (en) Crystalline forms of a purine derivative
HK1212333A1 (en) Crystalline forms of a factor xia inhibitor xia
PL2576505T3 (pl) Postać krystaliczna pleuromutyliny
HK1219415A1 (zh) 聯苯化合物的結晶游離碱形式
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
PL2578595T3 (pl) Krystaliczna lewoizowalerylospiramycyna I
SG10201501226VA (en) New crystalline form of a cyclopropyl benzamide derivative
HK1187394A1 (zh) 煤氣閥單元的結構
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
PL2407612T3 (pl) Zastosowanie skrzynki zbrojenia
ZA201300154B (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
HK1177459A1 (zh) 因子抑制劑的結晶鹽
HK1175780A1 (en) Crystalline cdc7 inhibitor salts cdc7
TWM390210U (en) Improved structure of a tool holder
TWM390844U (en) Structure improvement of a screwdriver
GB201004308D0 (en) New inhibitor compounds
TWM385440U (en) Structure improvement of a screwdriver
TWM402641U (en) Structure of a place box